News | February 08, 2022
GlaxoSmithKline Pharmaceuticals delivers strong financials in Q3FY22
EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.
EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.
Granules India has reported consolidated financial results for the period ended December 31, 2021
Aster DM Healthcare has reported consolidated financial results for the period ended December 31, 2021
Biosynthetic Technologies produces estolides, a new class of biobased synthetic oils used in a number of applications, including motor oil, industrial lubricants, pharmaceuticals, and personal care.
Key takeaways of recent quarter & conference call highlights
ImmunIgY, has been developed by ReaGene Biosciences, Kyntox Bio and ProdigY, and is an antibody-containing beverage that can potentially prevent viral entry, regardless of vaccination or infection status
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
The company has reported total income of Rs. 3715.8 crores during the quarter ended December 31, 2021
ICICI Direct’s analysis of Cipla’s Q3FY22 results
The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct
Subscribe To Our Newsletter & Stay Updated
